These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37959313)

  • 21. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation.
    Lee SH; Lee TW; Ihm CG; Kim MJ; Woo JT; Chung JH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S32-6. PubMed ID: 16174285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ischemia causes rapidly progressive nephropathy in the diabetic rat.
    Melin J; Hellberg O; Akyürek LM; Källskog O; Larsson E; Fellström BC
    Kidney Int; 1997 Oct; 52(4):985-91. PubMed ID: 9328937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study.
    Mora-Fernández C; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Pérez-Delgado N; Valiño-Rivas L; Fernández-Fernández B; Ortiz A; Navarro-González JF
    Biomed Pharmacother; 2022 Oct; 154():113677. PubMed ID: 36942605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
    Shimada K; Kanasaki K; Kato M; Ogura Y; Takagaki Y; Monno I; Hirai T; Kitada M; Koya D
    J Diabetes Investig; 2022 Jun; 13(6):955-964. PubMed ID: 35098679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond.
    Lahoti S; Nashawi M; Sheikh O; Massop D; Mir M; Chilton R
    Cardiovasc Endocrinol Metab; 2021 Mar; 10(1):3-13. PubMed ID: 33634250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors.
    Kogot-Levin A; Hinden L; Riahi Y; Israeli T; Tirosh B; Cerasi E; Mizrachi EB; Tam J; Mosenzon O; Leibowitz G
    Cell Rep; 2020 Jul; 32(4):107954. PubMed ID: 32726619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
    Hesp AC; Schaub JA; Prasad PV; Vallon V; Laverman GD; Bjornstad P; van Raalte DH
    Kidney Int; 2020 Sep; 98(3):579-589. PubMed ID: 32739206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
    Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
    Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
    Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-fibrosis therapy and diabetic nephropathy.
    Karihaloo A
    Curr Diab Rep; 2012 Aug; 12(4):414-22. PubMed ID: 22644874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
    Sano R; Ishii Y; Yamanaka M; Yasui Y; Kemmochi Y; Kuroki F; Sugimoto M; Fukuda S; Sasase T; Miyajima K; Nakae D; Ohta T
    Physiol Res; 2021 Mar; 70(1):45-54. PubMed ID: 33453716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model.
    Nakhoul N; Thawko T; Farber E; Dahan I; Tadmor H; Nakhoul R; Hanut A; Salameh G; Shagrawy I; Nakhoul F
    J Diabetes Res; 2020; 2020():7907605. PubMed ID: 33294462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. To Study the Incidence of Diabetic Retinopathy in Different Stages of Diabetic Nephropathy in Type 2 Diabetes Mellitus.
    Gopinath M; N PR; Hafeez M; An R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Novel Nonobese Type 2 Diabetes Rat Model with Enlarged Kidneys.
    Domon A; Katayama K; Tochigi Y; Suzuki H
    J Diabetes Res; 2019; 2019():8153140. PubMed ID: 31467929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of Kimmelstiel-Wilson nodule in the kidney outcome in patients with diabetic kidney disease: A two-center retrospective cohort study.
    Zhou Y; Chang DY; Li J; Shan Y; Huang XY; Zhang F; Luo Q; Xiong ZY; Zhao MH; Hou S; Chen M
    Diabetes Res Clin Pract; 2022 Aug; 190():109978. PubMed ID: 35809689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.